Tissue-specific, cell-mediated autoimmune diseases such as rheumatoid arthritis, type I diabetes or multiple sclerosis are widely believed to be mediated by autoreactive T helper lymphocytes. Until recently, multiple sclerosis and rheumatoid arthritis were recognized as being mediated by T helper type 1 (T H 1) cells, an idea supported by findings obtained with their respective animal models, experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis 1, 2 . In EAE, for example, disease can be induced in susceptible rodents by adoptive transfer of myelin-reactive T H 1 cells as well as by active immunization with myelin antigens. Nevertheless, the main evidence supporting the idea that pathogenic autoimmune cells are polarized T H 1 cells is based on the fact that tissue-invading T cells usually express interferon-g (IFN-g) 3, 4 . Furthermore, autoaggressive T H 2 cells were believed to have anti-encephalitogenic properties, and T H 2 immune deviation is widely considered a promising therapeutic strategy for the treatment of multiple sclerosis [5] [6] [7] .
However, a paradigm shift has occurred because of several key findings. First, IFN-g-deficient and tumor necrosis factor-deficient mice, for example, have been found to be susceptible to EAE [8] [9] [10] [11] . In fact, IFN-g deficiency even renders EAE-resistant mouse strains susceptible to EAE 9 . Second, although the p40 subunit of IL-12 is critical for the development of autoimmunity, its binding partner p35 is irrelevant 12 . That result is explained by the fact that p40 is also the large subunit of IL-23, which, in contrast to IL-12, is vital for autoimmunity 12 . Third, in contrast to IL-12, IL-23 is not a principal T H 1-inducing cytokine but instead drives the population expansion of IL-17-polarized T cells. IL-17, in contrast to IFN-g, is indeed firmly linked with encepahlopathogenicity 13, 14 .
Because IL-12 is no longer considered an essential factor for EAE, we wanted to assess the involvement of IL-18 in T H 1 cell polarization and EAE development. IL-18 is a proinflammatory cytokine and a member of the IL-1 'superfamily' of cytokines. Its main function during inflammation seems to be the polarization of T H 1 cells [15] [16] [17] . IL-18 is secreted by antigen-presenting cells (APCs) and signals through the IL-18 receptor (IL-18R), a heterodimer consisting of a ligand-binding IL-18Ra subunit and a signaling IL-18Rb subunit (also called IL-1RAcPL and IL-1R7). Signaling 'downstream' of IL-18R, like that of other IL-1 and Toll-like receptors, activates the kinase IRAK4 and adaptor molecule . IL-18R is expressed on lymphocytes as well as on accessory cells [21] [22] [23] [24] . Although it is firmly established that IL-18 can bind to the IL-18R complex, its affinity for IL-18Ra is weak 25, 26 . Given the protective activity of 27, 28) and IFN-g 29 , we sought to identify the function of IL-18 and IL-18Ra in central nervous system (CNS) autoimmunity.
Here we show that IL-18 did not exert a pathogenic effect in the development of EAE, as Il18 -/-mice were fully susceptible to EAE. However, deletion of its receptor (IL-18Ra) resulted in complete resistance to EAE, suggesting the presence of an alternative ligand with encephalitogenic properties. Loss of IL-18Ra affected neither the priming nor the population expansion of antigen-driven T cells. However, engagement of IL-18Ra on APCs was critical for the generation of IL-17-producing T helper cells (T H -17 cells) through an IL-23-dependent mechanism.
RESULTS
Mice deficient in both IL-12p35 and IL-18 develop EAE EAE is generally referred to as a T H 1 cell-mediated disease, yet deletion of IL-12, a chief T H 1-promoting cytokine, does not lead to resistance to EAE 12 . To assess whether IL-18 is capable of compensating for the loss of IL-12p35 and thus is responsible for the susceptibility of IL-12p35-deficient mice to EAE, we generated mice deficient in both IL-12p35 (Il12a -/-) and IL-18 (Il18 -/-). Immunization of mice with myelin oligodendrocyte glycoprotein peptide consisting of amino acids 35-55 (MOG(35-55)) emulsified in complete Freund's adjuvant (CFA) showed that Il12a -/-Il18 -/-mice were susceptible to EAE and had a disease severity and development similar to that of wild-type mice ( Table 1) . Immunization of wild-type and single-mutant Il18 -/-mice with MOG showed that Il18 -/-mice were also susceptible to EAE ( Fig. 1 and Table 1 ). Those results demonstrated that IL-18 is not responsible for the EAE susceptibility of Il12a -/-mice and indicated that IL-18 itself is a cytokine with little or no effect on EAE pathogenesis.
IL-18 is required for mitogen-but not antigen-driven immunity
To rule out the possible expression of a truncated yet functional form of IL-18, we extensively verified the targeting strategy and genotype of the mice. We established that Il18 -/-mice did not produce IL-18 mRNA by doing RT-PCR with primers outside the target of deletion. We also analyzed by enzyme-linked immunosorbent assay (ELISA) whether we could detect IL-18 secreted from activated splenocytes derived from wild-type and Il18 -/-mice; this showed that Il18 -/-mice were indeed completely deficient in IL-18 (Supplementary Fig. 1 online) . As noted in many experimental systems, deletion of IL-18 consistently results in the paucity of an IFN-g response 30, 31 . We thus stimulated lymphocytes derived from naive wild-type, Il18 -/-and Il18r1 -/-(IL-18Ra-deficient) mice in vitro for 16 h with the lectin concanavalin A and measured IFN-g production by ELISA. Consistent with the idea that IL-18 polarizes T H 1 cells, lymphocytes from Il18 -/-and Il18r1 -/-mice did not secrete IFNg, in contrast to wild-type lymphocytes (Fig. 2a) . We further verified that T cell function and activation during polyclonal stimulation was not directly impaired, as there was no difference in IFN-g secretion by stimulated wild-type, Il18 -/-and Il18r1 -/-purified CD4 + T cells ( Supplementary  Fig. 2 online) .
To establish the function of IL-18 and IL18Ra in adaptive antigen-driven immune responses, we immunized wild-type, Il18 -/-and Il18r1 -/-mice subcutaneously with MOG(35-55) in CFA or with keyhole limpet hemocyanin (KLH), as a large immunogenic protein antigen (of about 400 kilodaltons), in CFA and 7 d later isolated and restimulated lymphocytes with MOG or KLH in vitro. When we used KLH as immunogen, we did not find a significant difference in IFN-g production by lymphocytes from wild-type, Il18 -/-or Il18r1 -/-mice (Fig. 2b) . Immunization with MOG-peptide, however, resulted in Il18r1 -/-cells that produced significantly less IFN-g than did lymphocytes from wild-type or Il18 -/-mice. Those data supported the conclusion that although IL-18 and IL-18Ra are critical cofactors for the early IFN-g response of mitogen-or lectin-activated T cells, MOG(35-55)-induced responses showed discordant activity by lymphocytes lacking IL-18 or IL-18Ra. In contrast, activation and IFN-g production via the complex large protein antigen KLH seemed to be independent of IL-18 or IL-18Ra, a result in agreement with a published report demonstrating the redundant function of IL-18 in IFN-g production 32 .
Il18r1 -/-mice are resistant to EAE Mice deficient in IL-18Ra have been described as having an immunological phenotype similar to that of Il18 -/-mice 33 . However, we found that in contrast to wild-type and Il18 -/-mice, Il18r1 -/-mice were resistant to EAE induction ( Fig. 3 and Table 1 ). Histological analysis of spinal cords obtained 28 d after EAE induction showed that susceptible wild-type and Il18 -/-mice had considerable inflammation and demyelination of the CNS (Fig. 4) . More detailed analysis demonstrated infiltration of T cells, macrophages and B cells and axonal damage in the spinal cords of the mice (Fig. 4 and Supplementary Fig. 3 online) . In contrast, Il18r1 -/-mice showed no leukocyte infiltration or demyelination (Fig. 4 and Supplementary  Fig. 3 ). Quantitative RNA analysis of spinal cords from wild-type and Il18 -/-mice with EAE showed that in accordance with the presence of inflammatory infiltrates, they had increased local expression of chemokines and inflammatory cytokines ( Supplementary Fig. 3 ).
The different susceptibilities of Il18 -/-and Il18r1 -/-mice to EAE induction (Fig. 3a) indicates the possibility of an IL-18Ra ligand other than IL-18 with encephalitogenic properties. To verify that IL-18Ra and IL-18 have independent biological functions, we blocked IL-18Ra in EAE-susceptible Il18 -/-mice. Treatment of Il18 -/-mice with a monoclonal antibody to IL-18Ra 1 d before immunization and every 3 d thereafter until the end of the experiment significantly reduced disease development ( Fig. 3b) without causing deletion of IL-18Ra-expressing cells or altering the composition of peripheral leukocytes in the blood, lymph nodes or spleens (Supplementary Table 1 online). Treating Il18 -/-mice with the monoclonal antibody to IL-18Ra on day 10 after immunization also abrogated EAE progression ( Fig. 3c) , suggesting that IL-18Ra engagement is important during the effector phase of EAE. Therefore, blockade of IL-18Ra prevents EAE even in mice in which its proposed ligand is completely removed by gene targeting, and indeed IL-18 reportedly has a low affinity for IL-18Ra. Thus, we propose that an IL-18Ra ligand other than IL-18 is responsible for the engagement, signaling and immune development mediated by IL-18Ra.
Persistence of CNS inflammation and T H -17 cells requires IL-18Ra
EAE is characterized by a massive influx of inflammatory cells into the CNS at the peak of disease, yet immune cells also invade the CNS before the onset of clinical symptoms 34, 35 . For example, recruitment of CD4 + T cells into the CNS is critical for the initiation of the effector phase of EAE, whereas invasion of polymorphonuclear leukocytes seems to be involved in orchestrating these events 36 . Therefore, to establish the effect of IL-18Ra on the capacity of inflammatory cells to invade the CNS, we immunized mice with MOG(35-55) and analyzed their CNS for inflammatory infiltrates. In contrast to peak disease, when the Il18r1 -/-CNS was devoid of inflammatory infiltrates (Fig. 4) , on day 7 after immunization, the number of CNS-infiltrating leukocytes (CD45 hi cells) was similar in Il18r1 -/-, wild-type and Il18 -/-mice ( Fig. 5a ). Detailed analysis of the invading cells showed that comparable numbers of CD4 + T cells, granulocytes, macrophages and B cells were present in all three strains ( Supplementary Fig. 3 ). Because inflammatory cells are absent from the CNS during clinical disease, it seems that Il18r1 -/-inflammatory cells do not persist during the effector phase of the disease. Such results resemble those obtained with IL-23p19-deficient (Il23a -/-) mice and IL-23p40-deficient (Il12b -/-) mice, which are also resistant to MOG(35-55)-induced EAE and in which inflammatory cells are found in the CNS early after immunization but before disease begins 13, 37 .
Given the similarities between Il18r1 -/-and Il23 -/-mice regarding their EAE resistance with concomitant inflammatory cell invasion into the CNS, we assessed the effect of IL-18Ra on IL-17 production. T H -17 cells are now widely believed to be the main pathogenic population during autoimmune CNS inflammation 13, 14 . We therefore quantified IL-17-producing MOG-reactive T cells invading the CNS before and after clinical disease onset in mice immunized with MOG(35-55). Enzyme-linked immunospot analysis showed that immediately before disease onset (9 days after immunization), the number of MOG-specific IFN-g-secreting cells invading the CNS was similar in EAE-susceptible Il18 -/-and EAE-resistant Il18r1 -/-mice, whereas T H -17 cells were nearly completely absent from the Il18r1 -/-mice only (Fig. 5b) . After disease onset, moreover, although we detected increased numbers of IFN-g-and IL-17-secreting cells in the susceptible Il18 -/-and wild-type mice, these cells were almost completely absent from the Il18r1 -/-mice (Fig. 5c) .
To determine whether Il18r1 -/-mice are defective in generating IL-17-producing T cells, we analyzed IL-17 expression by freshly primed lymphocytes in vitro. We immunized wild-type, Il18 -/-and Il18r1 -/-mice with either MOG(35-55) or KLH and collected lymphocytes from the draining lymph nodes after 7 d. By real-time PCR analysis of mRNA obtained from lymphocytes after restimulation with MOG antigen, we found that the expression of IL-17 mRNA was significantly lower in Il18r1 -/-cells than in wild-type or Il18 -/-cells (Fig. 6a) . We corroborated those results by ELISA of cell culture media of lymphocytes rechallenged with MOG(35-55) in vitro, which demonstrated that IL-17 production was significantly lower for Il18r1 -/-but not Il18 -/-or wild-type lymphocytes (Fig. 6b) . In contrast to the production of IFN-g, which showed some dependence on the immunogenicity of the stimulating antigen, IL-17-secretion was consistently lower in the Il18r1 -/-leukocytes, even when KLH was used to immunize and restimulate the cells. Thus, the resistance of Il18r1 -/-mice to EAE could certainly derive from their inability to generate sufficient numbers of inflammatory T H -17 cells.
IL-18Ra expression on accessory cells
The results thus far have shown that IL-18Ra deficiency completely prevents the development of EAE and T H -17 cell polarization, whereas IL-18 seems to be irrelevant for both phenotypes. The cell type on which the IL-18Ra exerts its main effects remains unknown. This is due mainly to the fact that IL-18Ra is expressed by various cell types and tissues 21, 38, 39 . To identify the IL-18Ra-expressing cell type needed for EAE induction, we selectively expressed IL18Ra on cells in the leukocyte compartment using irradiation bone marrow chimeras. After irradiation and reconstitution, the immune compartment in secondary lymphoid tissues of recipient mice is composed of hematopoietic cells derived from donor mice 40, 41 . We generated bone marrow chimeras by transferring either a 4:1 ratio of recombination-activating gene 1-deficient (Rag1 -/-) and Il18r1 -/-bone marrow into wild-type recipients (Rag1 -/-+ Il18r1 -/--wild-type) or Il18r1 -/-bone marrow only into wild-type recipients (Il18r1 -/--wild-type); as a control, we also transferred wild-type bone marrow into wild-type recipients (wild-type -wild-type). Because Rag1 -/-mice do not have lymphocytes, all lymphocytes from the Rag1 -/-+ Il18r1 -/--wild-type chimera were IL-18Ra deficient, whereas most other nonlymphocyte leukocytes (accessory cells such as dendritic cells, macrophages, neutrophils and so on) expressed IL-18Ra.
As anticipated from the data above, Il18r1 -/--wild-type chimeric mice were resistant to EAE after immunization with MOG(35-55) (Fig. 7a) . However, the addition of Rag1 -/-bone marrow to the Il18r1 -/-bone marrow (Rag1 -/-+ Il18r1 -/--wild-type) resulted in susceptibility to EAE (Fig. 7a) . Thus, IL-18Ra expression on accessory cells is sufficient for EAE induction even when lymphoctyes are IL-18Ra deficient. Because IL-18Ra is present on myeloid cells 42 (such as APCs), we next tested the capacity of IL-18Ra-deficient APCs to prime naive T cells. We purified CD4 + T cells from 2d2 transgenic mice, which express a T cell receptor (TCR) specific for MOG , and cultured them together with mature, MOG(35-55)-pulsed, wild-type, Il18 -/-or Il18r1 -/-bone marrow-derived dendritic cells (DCs). We found no difference in the ability of the different DCs to stimulate proliferation of the 2d2 T cells (Fig. 7b) . To confirm that result in an in vivo setting, we injected carboxyfluorescein diacetate succinimidyl diester-labeled 2d2 cells into wild-type, Il18 -/-and Il18r1 -/-mice, immunized the mice with MOG(35-55) and then analyzed proliferation of the 2d2 cells. Again, we found no difference in proliferation of the 2d2 cells in wild-type, Il18 -/-and Il18r1 -/-mice (Fig. 7c) . Additional experiments with adoptive transfer of TCR-transgenic T cells confirmed that IL-18Ra deficiency on nonlymphocytic leukocytes reduced the generation of T H -17 cells ( Supplementary Fig. 4 online) .
To assess the ability of myeloid cells to reach the CNS tissue, we generated mixed bone marrow chimeras by transferring CD45 congenic wild-type and Il18r1 -/-bone marrow into wild-type recipients and evaluated the capacity of myeloid populations to invade the CNS during disease. We first confirmed that the mice had a 1:1 ratio of wild-type and Il18r1 -/-hematopoietic cells in peripheral blood and spleens. After EAE induction, we found both myeloid populations in the CNS at a ratio of 1:1, indicating that there was no migratory difference between the two genotypes of myeloid cells (data not shown). Expression of activation markers and costimulatory molecules by lipopolysaccharide-matured DCs from wild-type, Il18 -/-and Il18r1 -/-mice showed no difference in expression of CD80, CD86 and CD40 (data not shown). To confirm the function of IL-18Ra signaling in accessory cells during the effector phase of EAE, we adoptively transferred encephalitogenic MOG-reactive T cells derived from wildtype donor mice into both wild-type and Il18r1 -/-recipient mice. Fully primed and activated encephalitogenic T cells derived from wild-type mice induced EAE in wild-type recipient mice, yet they were incapable of inducing clinical EAE in IL-18Ra-deficient hosts (Fig. 7d) .
IL-18Ra-deficient APCs secrete limited IL-12,IL-23p40
As our results demonstrated a substantial decrease in IL-17 production by T cells after restimulation, we analyzed the capacity of Il18r1 -/-APCs to secrete IL-12,IL-23p40, which is necessary for the population expansion of pathogenic T H -17 cells. To measure p40 secretion, we stimulated T cell-depleted splenocyte samples with antibody to CD40 (anti-CD40) for 36 h before measuring p40 production by ELISA. We found that Il18r1 -/-APCs, like IL12 p40-deficient (Il12b -/-) APCs, had impaired p40 production, in contrast to high p40 production by wild-type and Il18 -/-APCs (Fig. 8a) . Finally, we confirmed the deficient IL-12,IL-23p40 production in an adaptive immune response by restimulating lymph node preparations from MOG-and KLH-immunized mice in vitro and analyzing p40 production after 2 d. As expected, there was significantly less production of p40 by Il18r1 -/-lymphocytes than by wild-type and Il18 -/-lymphocytes (Fig. 8b,c) . We failed to find significantly lower p19 expression by stimulated APCs, which indicated that the effect of IL-18Ra deficiency on T H -17 cells was probably regulated by the amount of p40 rather than p19 expression. In addition, we did not find lower transforming growth factor-b expression in Il18r1 -/-APCs (data not shown).
DISCUSSION
Organ-specific inflammatory diseases generally result from inappropriate population expansion and activation of effector T lymphocytes, which are capable of escaping peripheral tolerance and reacting to expressed self antigens. Until recently, T H 1 lymphocytes were thought to represent the autoreactive T cells responsible for inducing cellular autoimmunity [3] [4] [5] [6] [7] . However, mounting evidence indicates that T H -17 cells, not T H 1 cells, are the pathogenic T cell effectors in autoimmunity and that their development is negatively regulated by both T H 1 and T H 2 cytokines [12] [13] [14] 27, [43] [44] [45] . We were interested in characterizing the function of IL-18 in EAE. IL-18 acts in synergy with IL-12 in the differentiation of naive T H cells into T H 1 cells. Our initial goal was to determine if the EAE susceptibility of IL-12-deficient mice occurs as a result of redundancy, whereby the continued presence and activity of IL-18 in these mice is sufficient for EAE induction. Our data challenge that hypothesis, as Il12a -/-Il18 -/-double-deficient mice were fully susceptible to EAE. We also found that Il18 -/-mice were susceptible to EAE. That result contrasts with published data showing that Il18 -/-mice are resistant to EAE 38 . The discrepancy between our data and that earlier study could be explained by different health status of the mice or their degree of backcrossing onto the C57BL/6 background. Our results with Il18 -/-mice are also in agreement with other published data obtained with independently derived Il18 -/-mice showing susceptibility to experimental autoimmune uvitis using a methodology similar to that used in our study here 46, 47 . Thus, Il18 -/-mice are susceptible to EAE and experimental autoimmune uvitis by the standard methodology of induction of experimental autoimmunity. Finally, another report demonstrating that IL-18 is redundant in an antigen-induced arthritis model 32 directly supports our finding that IL-18 was unnecessary during antigen-induced T H 1 responses.
Despite the susceptibility of Il18 -/-mice, we found that Il18r1 -/-mice were resistant to EAE, which indicates that an IL-18Ra-binding ligand other than IL-18 has encephalitogenic properties. There are many 'orphan receptors' in the IL-1R 'superfamily' , and given that members of this family of receptor subunits form heterodimers with one another 48 , it is possible that IL-18Ra not only has different binding partners but also different ligands. We demonstrated the importance of IL-18Ra by significantly attenuating disease development in Il18 -/-mice using antibodies to IL-18Ra. Given that the known IL-18Ra ligand, IL-18, was not present in those mice, that result provides persuasive evidence for the existence of an alternative IL-18Ra ligand. Future studies should be aimed at identifying such an IL-18Ra-binding ligand as well as the composition of the ligand's full receptor complex.
The development of EAE in wild-type mice is dependent on the infiltration of activated CD4 + T cells into the CNS, an event that is accompanied by the influx of other immune cells, including B cells, macrophages and granulocytes [34] [35] [36] . In Il18r1 -/-mice, inflammatory cells were absent from the spinal cords at the peak of clinical EAE. However, we detected comparable CNS-invading leukocyte infiltration in both Il18r1 -/-and wild-type mice before disease onset. Therefore, IL-18Ra deficiency affects not the initial migratory properties of leukocytes but their persistence in the CNS. The presence of inflammatory infiltrates in the Il18r1 -/-CNS early after immunization, before the onset of clinical disease, is similar to the phenotype of Il23 -/-mice 37 , whose resistance to EAE probably results from their inability to expand populations of and maintain IL-17-producing T H cells 13, 37 .
One of our goals was to determine the mechanism of action of IL-18Ra activation and signaling during EAE. Published data have shown that the expression of IL-18Ra is broadly distributed 21, 38, 39 . In experiments with bone marrow chimeras, we demonstrated that the loss of IL-18Ra from an accessory cell was responsible for the loss of T H -17 cells. The importance of IL-18Ra on accessory cells was emphasized by adoptive transfer of otherwise encephalitogenic wildtype T cells that did not induce EAE in Il18r1 -/-mice. We generally found that T cell activation and population expansion were not affected by the loss of IL-18Ra and that IL-18Ra-deficient APCs had no difference in activation status. Finally, we demonstrated that IL-18Ra signaling on APCs was critical for the secretion of IL-23p40 and the subsequent maintenance of IL-17-secreting T cells. Our data thus support the hypothesis that IL-17 secretion is dependent on the continuous support of T H -17-promoting APCs.
In summary, we have provided evidence challenging the T H 1 paradigm of autoimmunity by demonstrating a nonpathogenic function for IL-18 in EAE. In contrast, however, we have shown that IL-18Ra is essential for the development of EAE, thus indicating the presence of an alternative IL-18Ra-binding ligand. Identification of the alternative IL-18Ra-binding ligand could provide a potent new therapeutic approach for the treatment of organ-specific inflammatory diseases such as multiple sclerosis. The attractive feature of this IL-18Ra-dependent pathway for therapeutic targeting is that its loss does not completely suppress immunity but instead abrogates the development of pathogenic autoimmune effector T cells.
METHODS
Mice. Female C57BL/6 mice were purchased from Harlan Laboratories. IL-12p35-deficent (Il12a -/-) mice and IL-12p40-deficient (Il12b -/-) mice were purchased from Jackson Laboratories. Homozygous Il18 -/-and Il18r1 -/-mice (backcrossed onto the C57BL/6 background for more than eight generations) were provided by S. Akira (Osaka University, Osaka, Japan) and Rag1 -/-mice were provided by R. Zinkernagel (University Hospital Zurich, Zurich, Switzerland) and were bred 'in-house' in specific pathogen-free conditions. The 2d2 (MOG-TCR-Tg) mice were provided by V. Kuchroo (Harvard Medical School, Boston, Massachusetts). Animal experiments were approved by the Swiss Veterinary Office (69/2003 and 70/2003; Zurich, Switzerland). Irradiation bone marrow-chimeric mice were generated as described 41 . Bone marrow donor mice were killed with CO 2 and bone marrow cells were isolated by flushing of femur, tibia, radius and hip bones with PBS. Bone marrow cells were then passed through a cell strainer with a pore size of 100 mm and cells were washed with PBS. Recipient mice were lethally irradiated with 1,100 rads (split dose) and were injected intravenously with 12 Â 10 6 to 25 Â 10 6 bone marrow cells. Engraftment took place over 8 weeks of recovery.
Induction of EAE. Mice were immunized subcutaneously with 200 mg of MOG(35-55) (MEVGWYRSPFSRVVHLYRNGK; obtained from GenScript) emulsified in CFA (Difco). Mice received 200 ng pertussis toxin (SigmaAldrich) intraperitoneally at the time of immunization and 48 h later. For adoptive transfer, MOG-reactive T cells were generated as described 40 . Monoclonal antibody to IL-18Ra (clone 112624; R&D Systems) was administered either 1 d before immunization (450 mg/mouse) and every 3 d thereafter (300 mg/mouse) or every 3 d beginning from disease onset (300 mg/mouse). Mice were assigned scores daily as follows: 0, no detectable signs of EAE; 0.5, distal tail limp; 1, complete tail limp; 2, unilateral partial hindlimb paralysis; 2.5, bilateral partial limb paralysis; 3, complete bilateral hindlimb paralysis; 3.5, complete hindlimb paralysis and unilateral forelimb paralysis; 4, total paralysis of forelimbs and hindlimbs (mice with a score above 4 to be killed); 5, death. Each time point presents the average disease score of each group. Statistical significance was assessed with an unpaired Student's t-test.
Histology and flow cytometry. Mice were perfused with PBS and then with 4% (weight/volume) paraformaldehyde in PBS. Spinal columns were removed and were fixed in 4% (weight/volume) paraformaldehyde in PBS. Spinal cords were then dissected and were embedded in paraffin before being stained with either hematoxylin and eosin or with anti-CD3 (145-2C11), anti-B220 (RA3-6B2) or anti-Mac-3 (M3/84; BD Pharmingen) to assess infiltration of inflammatory cells. Luxol fast blue stain was used to determine the degree of demyelination or amyloid precursor protein was used to assess the extent of axonal damage. For cytofluorometry, anti-CD45 (30/F11), anti-CD4 (RM4-5), anti-V a 3.2 (RR3-16), anti-CD11b (M1/70), anti-Gr-1 (RB6-8C5) and anti-B220 (RA3-6B2; BD Pharmingen) were used. For analysis of CNS-invading cells, mice were killed with CO 2 and were perfused intracardially with PBS as described 41 . Spinal cords were flushed out with PBS and brains were dissected to isolate the brainstem. Tissues were homogenized and strained through a nylon filter with a pore size of 100 mm (Fisher). After centrifugation, cell suspensions were resuspended in 30% Percoll (Pharmacia) and were centrifuged at 18,500g for 30 min at 4 1C. Interphase cells were collected and were washed extensively before being stained. For flow cytometry, antibodies were incubated with cells for 20 min at 4 1C and then cells were analyzed with a FACSCalibur (BD Pharmingen) and CellQuest software. Post-acquisition analysis was done with WinMDI 2.8 software (The Scripps Research Institute).
Proliferation and cytokine assays. Spleens and axillary and inguinal lymph nodes were isolated from naive mice or mice primed by injections of 100 mg/ flank of MOG or KLH (Sigma) emulsified in CFA 7 d earlier. Cells (2 Â 10 5 cells/well) were plated in triplicate in 96-well plates. For naive cells, 5 mg/ml of concanavalin A was used for 16 h of stimulation and 5 mg/ml of anti-CD40 (FGK) was used for 36 h of stimulation before analysis of cytokine production by ELISA. CD4 + T cells were purified from naive splenocyte samples with BD IMag Magnetic Beads (BD Pharmingen) and were stimulated for 36 h with 5 mg/ml of anti-CD3 (2c11) and 5 mg/ml of anti-CD28 (37N) before analysis of IFN-g production by ELISA. MOG-or KLH-reactive cells were stimulated in triplicate for 48 h with either 50 mg/ml of MOG or KLH, 5 mg/ml of concanavalin A, or medium, and 0.5 mCi/ml of [ 3 H]thymidine was added after 24 h for assessment of proliferative responses. Thymidine incorporation was assessed with a Filtermate Collecter (Applied Biosystems) and a scintillation and luminescence counter. For cytokine analysis, culture supernatants of identical 'sister' cultures were collected after 48 h and were analyzed in duplicate for IFN-g, IL-17 and IL-23p40 production by ELISA (Pharmingen). For real-time PCR analysis, RNA was isolated from restimulated cells by TRIzol extraction (Invitrogen).
Enzyme-linked immunospot analysis. Lymphocytes were isolated from the CNS of MOG(35-55)-immunized mice on days 9 and 14 after immunization by differential Percoll centrifugation as described above. Cells (2 Â 10 5 cells/well) were plated in complete RPMI medium containing 50 mg/ml of MOG in 96-well plates (Millipore) coated with 7.5 mg/ml of anti-IFN-g (AN18; Mabtech) or 2 mg/ml of anti-IL-17 (TC11-18H10; BD Pharmingen). Plates were incubated at 37 1C in 5% CO 2 for 18 h (anti-IL-17) or 20 h (anti-IFN-g), at which point cells were discarded and plates were washed with PBS. Then, 0.5 mg/ml of biotin-conjugated anti-IFN-g (R4-6A2; Mabtech) or 1 mg/ml of biotin-conjugated anti-IL-17 (TC11-8H4.1; BD Pharmingen) was added, followed by incubation at 25 1C for 2 h or 4 h, respectively. After plates were washed, streptavidin-alkaline phosphatase (Mabtech) was added, followed by incubation for 1 h at 25 1C. Plates were washed with PBS, and 100 ml of the substrate solution BCIP/NBTplus (5-bromo-4-chloro-3-indolylphosphatenitro blue tetrazolium; Biosource) was added to the wells, which were developed until distinct spots emerged. Plates were analyzed with an enzyme-linked immunospot reader (ImmunoSpot; CTL).
Generation of bone marrow-derived DCs. Bone marrow-derived DCs were generated as described 52 . Femurs from bone marrow donor mice were removed and bone marrow cells were isolated by flushing of the bones with PBS; cells were then filtered through a cell strainer with a pore size of 100 mm. Cells (2 Â 10 6 to 2.5 Â 10 6 cells in 10 ml) were cultured in RPMI medium containing 10% FCS with the addition of 10% conditioned medium obtained from X-63 cells transfected with a plasmid containing granulocyte-macrophage colony-stimulating factor (obtained from A. Rolink, University of Basle, Switzerland). After at least 6 d, bone marrow-derived DCs were matured with 1 mg/ml of lipopolysaccharide overnight; immature bone marrow-derived DCs were maintained in medium containing granulocyte-macrophage colonystimulating factor. Bone marrow-derived DCs were used from day 7 to day 9.
Transgenic T cell proliferation and polarization. For in vitro proliferation of transgenic T cells, spleens were collected from naive 2d2 mice and CD4 + T cells were purified with BD-IMag magnetic beads (BD Pharmingen). The purity of T cell isolation was verified by flow cytometry. The 2d2 T cells (1 Â 10 5 ) were cultured in a 96-well plate together with immature or mature bone marrow DCs (3 Â 10 3 to 10 Â 10 3 ). Before coculture, bone marrow DCs were pulsed for 3 h with 1 mg/ml of MOG in RPMI medium, then were washed and were irradiated with 2,000 rads. Unpulsed DCs were used as a control, as were T cells cultured alone. Cells were incubated for 4 d and [ 3 H]thymidine was added for the last 18 h of culture. For in vivo proliferation of TCR-transgenic cells, mice were injected intravenously with 25 Â 10 6 2d2 cells labeled with 10 mM carboxyfluorescein diacetate succinimidyl diester (Invitrogen-Molecular Probes) and were immunized subcutaneously by bilateral flank injection of 100 mg MOG(35-55) emulsified in CFA. After 4 d, mice were killed and lymph node cells were isolated and stained with antibody to the MOG transgenic TCR (anti-V a 3.2) before cytofluorometry.
